StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.99+0.19 (+1.13%)

Close on Nov 18, 2026Market cap $3.10BP/E –Yield –

Xeris Biopharma total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Xeris Biopharma's total debt was $252.59M at Jun 30, 2026. For fiscal 2025 it was $220.34M, down 5.1% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$220.34M-5.1%
FY2024Dec 31, 2024$232.11M+21.6%
FY2023Dec 31, 2023$190.93M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$252.59M+15.5%
Q1 FY2026Mar 31, 2026$221.22M-3.7%
Q4 FY2025Dec 31, 2025$220.34M-5.1%
Q3 FY2025Sep 30, 2025$219.47M+1357.6%
Q2 FY2025Jun 30, 2025$218.63M+14.5%
Q1 FY2025Mar 31, 2025$229.76M–
Q4 FY2024Dec 31, 2024$232.11M–
Q3 FY2024Sep 30, 2024$15.06M–
Q4 FY2023Dec 31, 2023$190.93M–

More Xeris Biopharma figures

See a number that looks wrong?